5 December 2024 - interim results
The company has issued its interim results covering the six months to 31 October and these have revealed a reduction in turnover to £30.9m (2023: £32.2m) with adjusted pre-tax profits declining to £3.2m (2023: £3.7m). The reduction in revenues reflected lower activity in the life sciences and biomedical markets although these markets have recently seen an upturn. The company has benefited from its diverse range of activities and a better performance from some of these have helped mitigate the decline referred to. Adjusted diluted earnings per share for the period . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
